IP Library Granted Patent US 10,016,382
Granted Patent B2
US 10,016,382 · App. 14/736,775 · Granted Jul 10, 2018

Method for decreasing skeletal muscle damage and/or oxidative stress in mammals

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,016,382
App. No.
14/736,775
Granted
Jul 10, 2018
Kind
B2
Abstract

A method for reducing muscle damage and/or oxidative stress in active mammals as disclosed. In one embodiment, the mammals are administered a carnitine supplement. The L-carnitine supplement may be administered without any other pharmaceutical or drug products. After physical activity the L-carnitine supplement can lower myoglobin, TBARS, and creatine kinase in the bloodstream.

Claims (17)

1. A method for decreasing skeletal muscle damage and/or oxidative stress during and after intense physical activity of an active canine, the method comprising administering to the active canine that is and/or has undergone physical activity that lasts at least 20 minutes and increases a heart rate from about 5% to about 150% or more of a resting heart rate and results in an intensity equivalent to at least 50% of the active canine's VO 2 max, an effective amount of an L-carnitine supplement, and wherein the L-carnitine is administered to the active canine in an amount from about 50 to about 250 mg per day.

2. A method as defined in claim 1 , wherein the L-carnitine supplement is administered without administering an amino acid supplement.

3. A method as defined in claim 1 , wherein the L-carnitine supplement is administered at least every one to three days.

4. A method as defined in claim 1 , wherein the L-carnitine supplement is administered daily.

5. A method as defined in claim 1 , wherein L-carnitine is administered to the active canine in an amount from 30 milligrams to 250 milligrams per dose.

6. A method as defined in claim 1 , wherein the L-carnitine supplement is administered orally.

7. A method as defined in claim 1 , wherein the L-carnitine supplement is combined with a food composition and administered to the active canine.

8. A method as defined in claim 1 , wherein the L-carnitine supplement comprises a solid.

9. A method as defined in claim 1 , wherein the L-carnitine supplement is administered to the active canine in an amount sufficient to inhibit increases in myoglobin amounts in blood after activity.

10. A method as defined in claim 1 , wherein the L-carnitine supplement is administered to the active canine in an amount sufficient to lower a fractional breakdown rate (FBR) in muscle samples and in an amount sufficient to increase lean mass.

11. A method as defined in claim 1 , wherein myoglobin amounts in blood are reduced by greater than 50% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

12. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient reduce thiobarbituric acid reactive substances amounts in blood by greater than 50% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

13. A method as defined in claim 1 , wherein thiobarbituric acid reactive substances amounts in blood are reduced by greater than 75% after activity in comparison to an active canine that is and/or has undergone the same physical activity that has not received the L-carnitine supplement.

14. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient to reduce peroxidation of membranes due to physical stress.

15. A method as defined in claim 1 , wherein the L-carnitine supplement is administered in an amount sufficient to decrease skeletal muscle damage and to decrease oxidative stress during and after physical activity.

16. A method as defined in claim 1 , wherein the L-carnitine supplement comprises a liquid.

17. A method as defined in claim 1 , wherein L-carnitine is administered to the active canine in an amount greater than about 2.0 mg/kg body weight per day to about 9.0 mg/kg body weight per day.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2022
From: LONZA CONSUMER HEALTH INC.
To: CAPSUGEL MANUFACTURING, LLC
Reel/Frame 061901/0528 →
CHANGE OF NAME Recorded Nov 29, 2022
From: CAPSUGEL MANUFACTURING, LLC
To: LONZA GREENWOOD LLC
Reel/Frame 062007/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2020
From: LONZA AMERICA INC.
To: LONZA NORTH AMERICA INC.
Reel/Frame 053076/0276 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2020
From: LONZA, LLC
To: LONZA AMERICA INC.
Reel/Frame 053076/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2020
From: LONZA NORTH AMERICA INC.
To: INTERHEALTH HOLDINGS II INC.
Reel/Frame 053076/0357 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2020
From: INTERHEALTH HOLDINGS II INC.
To: LONZA CONSUMER HEALTH INC.
Reel/Frame 053076/0500 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 051975 FRAME: 0564. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 25, 2020
From: LONZA INC.
To: LONZA, LLC
Reel/Frame 053037/0598 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2020
From: LONZA INC
To: LONZA LLC
Reel/Frame 051976/0564 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2018
From: OWEN, KEVIN; WOODWORTH, JASON C.; COLLINGS, GEORGE; COON, CRAIG; LOPEZ, JOHNNY
To: LONZA, INC.
Reel/Frame 045522/0616 →